


Evotec AG			
Buy ➔ Target price : 6.10 EUR vs 5.60 EUR オ	Est.chg	2016e	2017e
Price (11/09/2016) : 5.25 EUR Upside : 16 %	EPS	21.2%	6.4%

Outstanding Q3 results, adj. EBITDA more than quintupled yoy

Publication date 10.11.2016 17:30 Writing date 10.11.2016 17:03



-Evotec AG Re

ve to Health Care (R

Evotec AG Evotec A	G Relative to Health	Care (Rebased)	
Capital			
EVT GY EVTG.DE Market Cap (EURm) Enterprise value (EURm) Extrema 12 months Free Float (%)		2.90	683 722 - 5.25 ns
Performance (%)	1m	3m	12m
Absolute	3.2	25.4	27.7
Perf. rel. Country Index	3.2	27.2	41.3
Perf. rel. Health Care	3.2	25.4	27.7
P&L	12/16e	12/17e	12/18e
Sales (EURm)	163	174	182
EBITDA (EURm)	30.5	29.6	32.8
Current EBIT (EURm)	18.8	17.3	19.8
Attr. net profit (EURm)	12.8	10.5	12.8
Adjusted EPS (EUR)	0.10	0.08	0.10
Dividend (EUR)	0.00	0.00	0.00
P/E (x)	53.3	65.2	53.5
P/B (x)	3.4	3.3	3.1
Dividend Yield (%)	0.0	0.0	0.0
FCF yield (%)	1.4	1.8	2.3
EV/Sales (x)	4.43	4.09	3.84
EV/EBITDA (x)	23.7	24.1	21.3
EV/Current EBIT (x)	38.4	41.3	35.4
Gearing (%)	-13	-17	-22
Net Debt/EBITDA(x)	ns	ns	ns

FY Results

Next Events

28.03.2017

Q3 results: Top line up 37% yoy, EBITDA increases more than fivefold

Evotec posted outstanding Q3 results today (10 Nov). Revenue was up 37% yoy to \in 45m (Oddo Seydler est.: + 22% yoy to \in 40.5m), driven primarily by milestone payments as well as a strong performance in base business, and Sanofi's contribution. As milestone payments entail no costs, their significant contribution to revenue, along with increased capacity utilisation, strongly boosted the gross margin. Adj. EBITDA came in at \in 14.8m (margin: 33%) and was considerably above our estimate (\in 9.7m; 27% margin). Adj. more than quintupled vs the Q3 2015 level. Net income came in at \in 8.7m vs a loss of \in -2.9m Q3 2015.

Evotec also announced today a novel strategic partnership, LAB282, between Oxford University, Oxford University Innovation, Oxford Sciences Innovation/OSI (which will provide funding of £ 13m/€ 14+m) and Evotec to select and accelerate early-stage projects coming out of Oxford University. Evotec will exclusively contribute its drug discovery expertise and platforms to select projects and develop them further. Evotec will be entitled to equity in new LAB282 spin-out companies together with Oxford University and its academic researchers. Together with OSI Evotec will also have the right to co-invest in seed financing rounds.

9M 16 results already exceed full-year 2016 guidance ; strong initial outlook for 2017, but long-term prospects are more important

Evotec confirmed its full-year 2016 outlook to more than double adj. EBITDA. At \in 30.6m 9M 16 adj. EBITDA is already 1/ above 2016 consensus (Bloomberg: \in 24.4m), which suggests consensus will increase; and 2/ above Evotec's own target (double the 2015 level of \in 8.7m). Furthermore, the consensus estimate of c. \in 27m for 2017e is too low in our view (Oddo Seydler est.: c. \in 30m). The low consensus for 2017e may reflect conservative assumptions regarding milestone payments; but given Evotec's expanded partnership base, we do not expect the contribution from the milestone payments to decline. Management also stressed that its initial outlook for 2017 is strong. Another lever for margin improvement is GBP weakness post Brexit, as Evotec has a high cost base in the UK. In our view, only part of the full positive effect of a soft GBP will show up in 2016, as it was hedged. The positive impact should be more pronounced in 2017e.

While Evotec's expanded customer base clearly improves its short term prospects, several new, high-quality collaborations will further improve the long-term value of Evotec, which is more crucial, in our view. We also think that strategic partnerships such as LAB282 significantly contribute to the long-term value of Evotec and could be a blueprint for further such collaborations in the future.

Lifting our TP to € 6.10 on increased estimates; Buy rating confirmed

Having raised our full-year 2016e estimates, we now expect adj. EBITDA of \in 30.5m (\in 29m), which is not aggressive in our view. Given management's confident tone regarding 2017, we have also raised our estimates for 2017e. According to our updated SOTP-valuation, the current share price of c. \in 5.25 largely reflects the value of i/ the Execute business (i.e., carrying out services for partners); we calculate this business's NPV at \in 551m or \in 4.15/share; and ii/ net cash of c. \in 120m or \in 0.90/share (total: \in 4.95). This implies that EVT Innovate, a key value driver which represents substantial long-term potential for the company – is not being priced in at all by the market. We currently estimate the NPV of the Innovate business at \in 150m or \in 1.1/share, which is conservative in our view. Based on our updated SOTP-valuation, we lift our TP to \in 6.10 and reiterate our Buy recommendation.

Igor Kim,CFA (Analyst) +49 (69) 92 05 48 15 igor.kim@oddoseydler.com

Conflict of interests:

Oddo Securities, a division of Oddo et Cie, limited sharepartnership - Bank authorised by ACPR. Oddo & Cie and/or one of its subsidiaries could be in a conflict of interest situation with one or several of the groups mentioned in this publication. Please refer to the conflict of interests section at the end of this document.

This is a non-contractual document, it is strictly for the private use of the recipient, and the information it contains is based on sources we believe to be reliable, but whose accuracy and completeness cannot be guaranteed. The opinions given in the document reflect our appraisal at the time of publication and may therefore be revised at a later date.



EVTG.DE EVT GY	Bu	ıy				Price 5.2	5EUR	
Biotechnology Germany	Ups	ide 16.	.21%			TP 6.1	0EUR	
PER SHARE DATA (EUR)	12/11	12/12	12/13	12/14	12/15	12/16e	12/17e	12/18e
Adjusted EPS Reported EPS	0.05 0.05	0.03 0.03	-0.22 -0.22	-0.10 -0.10	0.13 0.13	0.10 0.10	0.08 0.08	0.10 0.10
Growth in EPS(%)	ns	-48.3%	ns	ns	ns	-22.5%	-18.2%	21.9%
Net dividend per share	0.00 0.02	0.00 0.04	0.00 -0.01	0.00	0.00 0.05	0.00 0.07	0.00 0.09	0.00 0.12
FCF to equity per share Book value per share	1.24	1.29	-0.01	-0.11 1.22	1.43	1.52	1.60	1.70
Number of shares market cap	118.32	118.32	130.13	130.13	130.13	130.13	130.13	130.13
Number of diluted shares VALUATION	118.32 12/11	118.32 12/12	130.13 12/13	130.13 12/14	130.13 12/15	130.13 12/16e	130.13 12/17e	130.13 12/18e
12m highest price	3.40	3.04	4.84	4.51	4.28	5.25	12/176	12/100
12m lowest price	1.72	1.97	2.09	2.57	3.20	2.90		
(*) Reference price	2.63	2.57	2.99	3.59	3.82	5.25	5.25	5.25
Capitalization Restated Net debt	312 -44.5	304 -45.1	390 -77.3	467 -64.8	497 -109.4	683 -26.1	683 -35.4	683 -47.9
Minorities (fair value)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial fixed assets (fair value)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Provisions Enterprise Value	42.1 309	47.3 306	42.7 355	32.2 435	64.7 452	64.7 722	64.7 712	64.7 700
P/E (x)	49.1	92.4	ns	ns	30.1	53.3	65.2	53.5
P/CF (x)	23.7	34.4	41.1	87.8	34.4	29.1	30.0	26.5
Net Yield (%)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FCF yield (%) P/B incl. GW (x)	0.7% 2.12	1.5% 1.99	ns 2.45	ns 2.95	1.3% 2.68	1.4% 3.45	1.8% 3.27	2.3% 3.09
P/B excl. GW (x)	2.97	2.75	3.28	4.11	3.55	4.48	4.19	3.89
EV/Sales (x)	3.86	3.50	4.13	4.86	3.54	4.43	4.09	3.84
EV/EBITDA (x) EV/EBIT (x)	25.8 53.6	29.9 218	34.1 289	56.4 ns	52.0 ns	23.7 38.4	24.1 41.3	21.3 35.4
(*) historical average price								
PROFIT AND LOSS (EURm) Sales	12/11 80	12/12 87	12/13 86	12/14 89	12/15 128	12/16e 163	12/17e 174	12/18e 182
EBITDA	12.0	10.2	10.4	7.7	8.7	30.5	29.6	32.8
Depreciations	-6.2	-8.8	-9.2	-8.5	-11.9	-11.7	-12.3	-13.0
Current EBIT Published EBIT	5.8 4.8	1.4 -2.4	1.2 -24.4	-0.8 -12.1	-3.3 11.6	18.8 18.8	17.3 17.3	19.8 19.8
Net financial income	0.0	-1.8	-2.3	1.2	0.9	-1.7	-2.0	-1.2
Corporate Tax	1.4	7.5	-1.8	-1.8	4.0	-5.3	-4.7	-5.8
Net income of equity-accounted companies Profit/loss of discontinued activities (after tax)	0.0 0.0	0.0 0.0	0.0 0.0	0.0 0.0	0.0 0.0	0.0 0.0	0.0 0.0	0.0 0.0
Minority interests	0.1	0.0	0.0	0.0	0.0	1.0	0.0	0.0
Attributable net profit	6.3	3.3	-28.5	-12.6	16.5	12.8	10.5	12.8
Adjusted attributable net profit BALANCE SHEET (EURm)	6.3 12/11	3.3 12/12	-28.5 12/13	-12.6 12/14	16.5 12/15	12.8 12/16e	10.5 12/17e	12.8 12/18e
Goodwill	42.2	42.3	40.1	44.8	45.6	45.6	45.6	45.6
Other intangible assets	67.7	63.3	39.8	30.2	25.2	26.5	27.2	28.0
Tangible fixed assets WCR	24.9 6.2	27.2 17.5	24.2 18.1	24.0 25.5	38.3 21.1	38.0 25.4	37.5 26.4	36.0 27.3
Financial assets	3.9	4.4	2.1	1.2	12.0	12.0	12.0	12.0
Ordinary shareholders equity Minority interests	147 0.0	153 0.0	159 0.0	158 0.0	186 1.6	198 0.6	209 0.6	221 0.6
Shareholders equity	147	153	159	158	187	199	209	222
Non-current provisions	42.1	47.3	42.7	32.2	64.7	64.7	64.7	64.7
Net debt CASH FLOW STATEMENT (EURm)	-44.5 12/11	-45.1 12/12	-77.3 12/13	-64.8 12/14	-109.4 12/15	-26.1 12/16e	-35.4 12/17e	-47.9 12/18e
EBITDA	12.0	10.2	10.4	7.7	8.7	30.5	29.6	32.8
Change in WCR	-3.4	3.9	-5.8	-14.8	3.2	-4.3	-1.0	-0.9
Interests & taxes Others	-1.2 2.4	-0.9 -0.5	-0.6 -0.3	0.8 -3.2	-1.4 7.1	-7.2 0.0	-6.8 0.0	-7.0 0.0
Operating Cash flow	9.7	12.8	3.6	-9.5	17.6	19.0	21.8	24.9
CAPEX	-7.6	-8.1	-4.6	-5.3	-11.2	-9.7	-9.5	-9.3
Free cash-flow Acquisitions / disposals	2.2 -7.5	4.6 15.9	-0.9 -27.0	-14.8 7.2	6.5 -11.9	9.3 0.0	12.3 0.0	15.6 0.0
Dividends	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net capital increase	-0.1	-0.1	32.0	4.0	6.0	8.0	10.0	12.0
Others Change in net debt	1.7 -7.3	3.7 20.2	1.4 5.7	3.9 -2.9	3.6 2.7	0.0 14.3	0.0 19.3	0.0 24.5
GROWTH MARGINS PRODUCTIVITY	12/11	12/12	12/13	12/14	12/15	12/16e	12/17e	12/18e
Sales growth	45.0%	8.9%	-1.5%	4.1%	42.7%	27.5%	7.0%	4.6%
Lfl sales growth Current EBIT growth	ns	-75.7%	-12.3%	ns -	ns -	- ns	-8.2%	- 14.6%
Growth in EPS(%)	ns	-48.3%	ns	ns	ns	-22.5%	-18.2%	21.9%
Net margin	7.9%	3.8%	-33.1%	-14.1%	12.9%	7.9%	6.0%	7.0%
EBITDA margin Current EBIT margin	14.9% 7.2%	11.7% 1.6%	12.1% 1.4%	8.6% -0.9%	6.8% -2.5%	18.7% 11.6%	17.0% 9.9%	18.0% 10.9%
CAPEX / Sales	-10.2%	-9.4%	-6.0%	-5.9%	-8.7%	-5.9%	-5.5%	-5.1%
WCR / Sales Tax Rate	7.7%	20.1%	21.0%	28.5% -78.8%	16.5% -20.4%	15.6% 30.8%	15.2% 31.2%	15.0% 31.2%
Normative tax rate	-25.8%	ns	ns	-10.0%	-20.4%	30.0%	31.2%	31.2%
Asset Turnover	0.6	0.6	0.6	0.7	1.0	1.2	1.3	1.3
ROCE post-tax (normative tax rate)	-	-	-	-	-	-	-	-
ROCE post-tax hors GW (normative tax rate) ROE	4.5%	- 2.2%	- -18.3%	-8.0%	- 9.6%	- 6.7%	- 5.1%	- 5.9%
DEBT RATIOS	12/11	12/12	12/13	12/14	12/15	12/16e	12/17e	12/18e
Gearing Net Debt / Market Cap	-30% -0.14	-30% -0.15	-49% -0.20	-41% -0.14	-58% -0.22	-13% -0.04	-17% -0.05	-22% -0.07
Net debt / EBITDA	-0.14 ns	-0.15 ns	-0.20 ns	-0.14 ns	-0.22 ns	-0.04 ns	-0.05 ns	-0.07 ns
EBITDA / net financial charges	8.3	8.5	6.5	6.7	7.3	50.8	121.6	134.9



Mention of conflicts of interest

• Valuation method

Our target prices are established on a 12-month timeframe and we use three valuation methods to determine them. First, the discounting of available cash flows using the discounting parameters set by the Group and indicated on Oddo Securities' website. Second, the sum-of-the-parts method based on the most pertinent financial aggregate depending on the sector of activity. Third, we also use the peer comparison method which facilitates an evaluation of the company relative to similar businesses, either because they operate in identical sectors (and are therefore in competition with one another) or because they benefit from comparable financial dynamics. A mixture of these valuation methods may be used in specific instances to more accurately reflect the specific characteristics of each company covered, thereby fine-tuning its evaluation.

Our stock market recommendations

Our stock market recommendations reflect the RELATIVE performance expected for each stock on a 12-month timeframe. Buy: performance expected to exceed that of the benchmark index, sectoral (large caps) or other (small and mid caps). Neutral: performance expected to be comparable to that of the benchmark index, sectoral (large caps) or other (small and mid caps). Reduce: performance expected to fall short of that of the benchmark index, sectoral (large caps) or other (small and mid caps).

- The prices of the financial instruments used and mentioned in this document are the closing prices.
- All publications by Oddo Securities or Oddo Seydler concerning the companies covered and mentioned in this document are available on the research site:
 www.oddosecurities.com

Recommendation and target price changes history over the last 12 months for the company analysed in this report

Date	Reco	Price Target (EUR)	Price (EUR)	Analyst
10.11.16	Buy	6.10	5.25	Igor Kim,CFA
29.09.16	Buy	5.60	5.03	Igor Kim,CFA
12.08.16	Buy	5.40	4.36	Igor Kim,CFA
19.07.16	Buy	5.00	4.09	Igor Kim,CFA
10.05.16	Buy	4.90	3.56	Igor Kim,CFA
29.01.16	Buy	4.60	3.42	Igor Kim,CFA

Recommend	lation s	split
-----------	----------	-------

		Buy	Neutral	Reduce
Our whole coverage	(414)	49%	40%	11%
Liquidity providers coverage	(147)	53%	41%	5%
Research service coverage	(66)	65%	32%	3%
Investment banking services	(33)	70%	27%	3%

Risk of conflict of interest :

Investment banking and/or Distribution	
Has Oddo Group, or Oddo & Cie, or Oddo Seydler managed or co-managed in the past 12 months a public offering of securities for the subject company/ies?	No
Has Oddo Group, or Oddo & Cie, or Oddo Seydler received compensation for investment banking services from the subject company/ies in the past 12 months or expects to receive or intends to seek compensation for investment banking services from the subject company/ies in the last 12 months?	No
Research contract between Oddo group & the issuer	
Oddo & Cie and the issuer have agreed that Oddo & Cie will produce and disseminate investment recommendations on the said issuer as a service to the issuer	Yes
Liquidity provider agreement and market-making	
At the date of the distribution of this report, does Oddo Group, or Oddo & Cie, or Oddo Seydler act as a market maker or has Oddo Group or Oddo & Cie, or Oddo Seydler signed a liquidity provider agreement with the subject company/ies?	Yes
Significant equity stake	
Does Oddo Group, or Oddo & Cie, or Oddo Seydler own 5% or more of any class of common equity securities of the subject company/ies?	No
Does the subject company beneficially own 5% or more of any class of common equity of Oddo & Cie or its affiliates?	No
Disclosure to Company	
Has a copy of this report ; with the target price and/or rating removed, been presented to the subject company/ies prior to its distribution, for the sole purpose of verifying the accuracy of factual statements ?	No
Have the conclusions of this report been amended following disclosure to the company/ies and prior its distribution?	No
Additional material conflicts	
Is Oddo Group, or Oddo & Cie, or Oddo Seydler aware of any additional material conflict of interest?	No

Statement of conflict of interests of all companies mentioned in this document may be consulted on Oddo & Cie's: www.oddosecurities.com



Disclaimer:

Disclaimer for Distribution by Oddo & Cie to Non-United States Investors:

This research publication is produced by Oddo Securities ("Oddo Securities"), a division of Oddo & Cie ("ODDO"), which is licensed by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the Autorité des Marchés Financiers ("AMF"), and/or by ODDO SEYDLER BANK AG ("Oddo Seydler"), a German subsidiary of ODDO, regulated by Bundesanstalt für Finanzdienstleistungsaufsicht ("BaFin").

The research, when distributed outside of the U.S., is intended exclusively for non-U.S. customers of ODDO and cannot be divulged to a third-party without prior written consent of ODDO. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment.

This research has been prepared in accordance with regulatory provisions designed to promote the independence of investment research. "Chinese walls" (information barriers) have been implemented to avert the unauthorized dissemination of confidential information and to prevent and manage situations of conflict of interest. This research has been prepared in accordance with French and German regulatory provisions designed to promote the independence of investment research. This recommendation presented into this document is reviewed and updated at least following each Quarterly Report published by the issuer purpose of this Research Report. At the time of publication of this document, ODDO and/or Oddo Seydler, and/or one of its subsidiaries may have a conflict of interest with the insuer(s) mentioned. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy

At the time of publication of this document, ODDO and/or Oddo Seydler, and/or one of its subsidiaries may have a conflict of interest with the issuer(s) mentioned. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such. Past performances offer no guarantee as to future performances. All opinions expressed in the present document reflect the current context and which is subject to change without notice. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities and/or issuers and no part of his compensation was, is, or will be directly or indirectly related to the specific views contained in the research report.

This research report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice.

Disclaimer for Distribution by Oddo New York to United States Investors:

This research publication is produced by Oddo Securities, a division of ODDO and/or by Oddo Seydler.

This research is distributed to U.S. investors exclusively by Oddo New York Corporation ("ONY"), MEMBER: FINRA/SIPC, and is intended exclusively for U.S. customers of ONY and cannot be divulged to a third-party without prior written consent of ONY. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment.

This research has been prepared in accordance with regulatory provisions designed to promote the independence of investment research. "Chinese walls" (information barriers) have been implemented to avert the unauthorized dissemination of conflict normation and to prevent and manage situations of conflict of interest. This research has been prepared in accordance with French and German regulatory provisions designed to promote the independence of investment research.

At the time of publication of this document, ODDO and/or Oddo Seydler, and/or one of its subsidiaries may have a conflict of interest with the issuer(s) mentioned. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such. Past performances offer no guarantee as to future performances. All opinions expressed in the present document reflect the current context and which is subject to change without notice.

Rule 15a-6 Disclosure:

Under Rule 15a-6(a)(3), any transactions conducted by ODDO and/or Oddo Seydler, and/or one of its subsidiaries with U.S. persons in the securities described in this foreign research must be effected through ONY. As a member of FINRA, ONY has reviewed this material for distribution to U.S. persons as required by FINRA Rules 2241(h) applicable to dissemination of research produced by its affiliate ODDO. FINRA Disclosures:

• Neither ONY, ODDO, nor Oddo Securities, nor Oddo Seydler beneficially owns 1% or more of any class of common equity securities of the subject company.

The research analyst of Oddo Securities or Oddo Seydler, at the time of publication of this research report, is not aware, nor does he know or have reason to know of any actual, material conflict of interest of himself, ODDO, Oddo Securities, Oddo Seydler or ONY, except those mentioned in the paragraph entitled "Risk of Conflict of Interest."
Oddo Securities or ODDO or Oddo Seydler may receive or seek compensation for investment banking services in the next 3 months from the subject company of this research report, but ONY would not participate in those arrangements.

 Neither ONY, ODD, Oddo Securities, nor Oddo Seydler has received compensation from the subject company in the past 12 months for providing investment banking services except those mentioned in the paragraph of "Risk of Conflict of Interest".

• Neither ONY., ODDO, Oddo Securities nor Oddo Seydler has managed or co-managed a public offering of securities for the subject company in the past 12 months except those mentioned in the paragraph of "Risk of Conflict of Interest".

• ONY does not make (and never has made) markets and, accordingly, was not making a market in the subject company's securities at the time that this research report was published.

Regulation AC:

ONY is exempt from the certification requirements of Regulation AC for its distribution to a U.S. person in the United States of this research report that is prepared by an Oddo Securities research analyst because ODDO has no officers or persons performing similar functions or employees in common with ONY and ONY maintains and enforces written policies and procedures reasonably designed to prevent it, any controlling persons, officers or persons performing similar functions, and employees of ONY from influencing the activities of the third party research analyst and the content of research reports prepared by the third party research analyst.

Contact Information of firm distributing research to U.S. investors: Oddo New York Corporation, MEMBER: FINRA/SIPC, is a wholly owned subsidiary of Oddo & Cie; Philippe Bouclainville, President (pbouclainville@oddony.com) 150 East 52nd Street New York, NY 10022 212-481-4002.